CoChat

Therapeutics Targeting p53-MDM2 Interaction to Induce Cancer Cell Death

Open access
Koo, Nayeong, Sharma, Arun K., Narayan, Satya · 2022 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 131 of the 135 references it cites were found in a registry or an index, and 1 are not checked yet.

Abstract

Named as the guardian of the genome, p53 is a tumor suppressor that regulates cell function, often through many different mechanisms such as DNA repair, apoptosis, cell cycle arrest, senescence, metabolism, and autophagy. One of the genes that p53 activates is MDM2, which forms a negative feedback loop since MDM2 induces the degradation of p53. When p53 activity is inhibited, damaged cells do not undergo cell cycle arrest or apoptosis. As 50% of human cancers inactivate p53 by mutation, current research focuses on reactivating p53 by developing drugs that target the p53-MDM2 interaction, which includes the binding of MDM2 and phosphorylation of p53. The objective of this article is to provide a short list and description of p53-MDM2 antagonists that may be excellent candidates for inducing cancer cell death. Relevant articles were searched for and identified using online databases such as PubMed and ScienceDirect. Increasing p53 levels, by targeting the p53-MDM2 interaction, can help p53 play its role as a tumor suppressor and induce cancer cell death. Researchers have identified different compounds that can act as inhibitors, either by directly binding to MDM2 or by modifying p53 with phosphorylation. The results associated with the drugs demonstrate the importance of targeting such interactions to inhibit cancer cell growth, which indicates that the use of the compounds may improve cancer therapeutics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms23095005

Cites

131 of 132 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Structural features of p53: (A) different domains of p53. The Ser-15 and Ser-20 of the N-terminal activation domain (1–61), or TAD1 and TAD2, undergo phosphorylation and are the specific sites for interaction with MDM2 for ubiquitination and degradation of p53, although Mdm2 can bind to other domains, such as the C-terminal domain. Other domains include the proline rich domain (64–92), the DNA-binding domain (DBD) (100–300), the oligomerization domain (323–355), and the C-terminal domain (364–393); (B) the DNA-binding domain (DBD) of p53 with the absence of DNA. The bound zinc ion is shown as a brown sphere. The β-sheet and α-helix are displayed in green and red, respectively. The N-terminal activation domain (N) and the C-terminal domain (C) are labeled in grey.
Figure 1 Structural features of p53: (A) different domains of p53. The Ser-15 and Ser-20 of the N-terminal activation domain (1–61), or TAD1 and TAD2, undergo phosphorylation and are the specific sites for interaction with MDM2 for ubiquitination and degradation of p53, although Mdm2 can bind to other domains, such as the C-terminal domain. Other domains include the proline rich domain (64–92), the DNA-binding domain (DBD) (100–300), the oligomerization domain (323–355), and the C-terminal domain (364–393); (B) the DNA-binding domain (DBD) of p53 with the absence of DNA. The bound zinc ion is shown as a brown sphere. The β-sheet and α-helix are displayed in green and red, respectively. The N-terminal activation domain (N) and the C-terminal domain (C) are labeled in grey.CC BY · PubMed Central
Figure 2 Structures of the MDM2 gene and protein. The 3D structure of a portion of MDM2 protein (17–111) is shown below, which consists of the N-terminal p53-binding domain (19–108). The MDM2 gene consists of two promoters and 10 additional exons. Between exons 1 and 2, or the first intron, there are two p53 response elements (REs), which are the two p53-binding sites. The REs are shown with red arrows. The full-length MDM2 protein p90 is produced by starting from ATG of exon 3, while the shorter protein, or p76, is synthesized with the start codon on exon 4.
Figure 2 Structures of the MDM2 gene and protein. The 3D structure of a portion of MDM2 protein (17–111) is shown below, which consists of the N-terminal p53-binding domain (19–108). The MDM2 gene consists of two promoters and 10 additional exons. Between exons 1 and 2, or the first intron, there are two p53 response elements (REs), which are the two p53-binding sites. The REs are shown with red arrows. The full-length MDM2 protein p90 is produced by starting from ATG of exon 3, while the shorter protein, or p76, is synthesized with the start codon on exon 4.CC BY · PubMed Central
Figure 3 The mechanism of p53- and MDM2-binding. MDM2, indicated as black, binds to p53 at the N-terminal activation domain of p53, or the red area, to form p53/MDM2 complex. The two proteins are in direct contact via hydrogen bonding, with hydrophobic p53 residues Phe19, Trp23 and Leu26 that help such interaction. The structure of the p53/MDM2 complex, which is shown with the corresponding colors, black and red, leads to the ubiquitination and the proteasomal degradation of p53. This results in the inhibition of the transcriptional activity of p53.
Figure 3 The mechanism of p53- and MDM2-binding. MDM2, indicated as black, binds to p53 at the N-terminal activation domain of p53, or the red area, to form p53/MDM2 complex. The two proteins are in direct contact via hydrogen bonding, with hydrophobic p53 residues Phe19, Trp23 and Leu26 that help such interaction. The structure of the p53/MDM2 complex, which is shown with the corresponding colors, black and red, leads to the ubiquitination and the proteasomal degradation of p53. This results in the inhibition of the transcriptional activity of p53.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 155

Metadata

Authors
Koo, N., Sharma, A. K., & Narayan, S.
Affiliations
  • University of Florida (US)
  • Penn State Cancer Institute (US)
Corresponding author
Narayan, Satya
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2022-04-30
Volume
23
Issue
9
Pages
5005
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4225255854
Cited by
153
References
135
Citations by year
2026: 32 · 2025: 46 · 2024: 43 · 2023: 19 · 2022: 13
FWCI
3.75
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Department of Anatomy and Cell Biology, University of Florida
  • Department of Pharmacology, Penn State University College of Medicine
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Keywords
p53, MDM2, p53-MDM2 interaction, p53 reactivation, MDM2 inhibitors, p53 phosphorylation, tumor suppressor, cancer cell death, apoptosis, cell cycle arrest, cancer therapeutics
MeSH terms
Antineoplastic Agents, Humans, Neoplasms, Tumor Suppressor Protein p53, Cell Death, Apoptosis, Proto-Oncogene Proteins c-mdm2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.